How Tirzepatide Works: A Dual GIP/GLP-1 Receptor Agonist

Tirzepatide's mechanism of action centres on its ability to bind and activate two hormone receptors simultaneously. The GIP receptor, also known as the glucose-dependent insulinotropic polypeptide receptor, and the GLP-1 receptor each play distinct roles in metabolic regulation. When both receptors are activated together, they produce coordinated effects on appetite signalling, glucose homeostasis, and energy expenditure. This dual-agonism approach differs fundamentally from earlier peptides that targeted only the GLP-1 receptor, offering a more comprehensive metabolic intervention.

The discovery that combining GIP and GLP-1 activation yields superior metabolic outcomes emerged from decades of incretin hormone research. Incretin hormones are gut-derived peptides released in response to nutrient intake, particularly glucose. They account for 50-70% of the total insulin secretion following oral nutrient intake. By enhancing both GIP and GLP-1 signalling, tirzepatide amplifies these natural physiological mechanisms.

Once tirzepatide binds to GIP and GLP-1 receptors on target cells, it initiates intracellular signalling cascades. These cascades involve G-protein coupled receptor pathways that regulate adenylyl cyclase and protein kinase A. In pancreatic beta cells, this signalling enhances glucose-stimulated insulin secretion—meaning insulin is released primarily when blood glucose is elevated. This glucose-dependent mechanism helps explain why tirzepatide demonstrates a favourable safety profile regarding hypoglycaemia compared to insulin secretagogues.

In the brain, particularly the hypothalamus, tirzepatide activation of GIP and GLP-1 receptors modulates appetite centres and promotes satiety signalling. The peptide influences pro-opiomelanocortin (POMC) neurons, which are central to energy homeostasis, while simultaneously suppressing agouti-related peptide (AgRP) neurons that drive hunger. This dual inhibition-stimulation pattern creates a powerful appetite-suppressive effect. Additionally, slowed gastric emptying—the rate at which the stomach empties into the small intestine—contributes to prolonged postprandial satiety.

GLP-1 (glucagon-like peptide-1) receptors are distributed throughout the body, with highest expression in the pancreatic islets, brain, and gastrointestinal tract. GLP-1 signalling promotes insulin secretion, suppresses glucagon release, slows gastric emptying, and enhances satiety. The GLP-1 pathway has been extensively validated through prior peptides such as semaglutide and liraglutide. GIP receptors, historically considered less important than GLP-1 receptors, are similarly distributed and activate overlapping but distinct intracellular pathways.

Research has shown that GIP receptors contribute substantially to glucose regulation and appetite control independently. Notably, GIP's effects on insulin secretion are also glucose-dependent, reducing hypoglycaemia risk. The synergistic activation of both receptors by tirzepatide produces metabolic effects that exceed what either single agonist achieves alone—a finding supported by direct comparative trials.

Tirzepatide is a 39-amino-acid peptide administered as a once-weekly subcutaneous injection. Following injection, the peptide enters the systemic circulation and distributes to receptor-expressing tissues. The majority of tirzepatide elimination occurs via proteolytic degradation and peptide metabolism, typical for peptide therapeutics. Peak plasma concentrations are achieved 8-10 days after injection due to subcutaneous depot formation and gradual absorption.

The once-weekly dosing regimen, compared to the twice-daily or once-daily dosing required by some earlier peptides, reflects tirzepatide's extended half-life and receptor interaction properties. Steady-state plasma concentrations accumulate over several weeks with repeated weekly dosing. This pharmacokinetic profile supports consistent receptor occupancy and metabolic effects throughout the inter-dose interval.

Multiple clinical trials have demonstrated that tirzepatide's dual-agonist mechanism translates into measurable metabolic benefits. The SURMOUNT trials for weight management and the SURPASS trials for type 2 diabetes both showed tirzepatide's superiority over GLP-1-only agonists in their respective primary endpoints. The weight-loss efficacy observed in SURMOUNT trials exceeded that of semaglutide, a GLP-1-only agonist, despite similar baseline characteristics.

In the SURPASS trials, tirzepatide demonstrated superior glycaemic control and reductions in HbA1c compared to other GLP-1 receptor agonists. These outcomes support the hypothesis that dual GIP/GLP-1 agonism provides additive or synergistic metabolic benefit. However, the precise mechanisms driving this superiority—whether primarily appetite-related, insulin-secretion-related, or glucagon-suppression-related—remain partially elucidated in human studies.

While tirzepatide's mechanism is understood at a cellular and pharmacological level, several questions remain incompletely answered in human research. The relative contribution of GIP versus GLP-1 activation to weight loss in humans has not been fully delineated. Animal studies and receptor occupancy experiments suggest both pathways contribute, but quantifying their individual contributions in living human metabolism is technically challenging.

Additionally, long-term metabolic adaptations to sustained dual-agonist therapy are still being characterised. Some research suggests the body may develop compensatory mechanisms over extended treatment periods, though clinical trial data to date have not revealed severe tachyphylaxis. The mechanistic understanding will likely deepen as longer-term follow-up data accumulate and as structure-activity relationship studies refine future generations of dual agonists.